Aptose enters $8.5M loan agreement with Hanmi for tuspetinib AML development

Aptose Biosciences Inc.

Loan agreement with Hanmi for up to US$8.5M uncommitted facility to fund continued clinical development of tuspetinib.
Loan is a related-party transaction; Aptose relies on 'financial hardship' exemption from formal valuation and minority shareholder approval.
Tuspetinib is an oral agent targeting SYK, FLT3, KIT, JAK1/2, RSK2; ongoing TUSCANY Phase 1/2 trial in newly diagnosed AML with azacitidine and venetoclax.
Early data from first two dose cohorts showed safety, CRs, and MRD negativity across diverse mutations.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.